All In Biotech

NDA 020978 · Viiv Hlthcare

Ziagen

Abacavir Sulfate · Oral

Accelerated approvalPriority review

Last checked: Nov 20, 2026Latest source record: Nov 24, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1998

Dec 17, 1998

Approved uses

6

Original approval plus efficacy supplements

Registered trials

239

79 Phase 3, 5 recruiting

FAERS reports

4,037

3,693 serious, 501 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: HYPERSENSITIVITY REACTIONS Serious and sometimes fatal hypersensitivity reactions, with multiple organ involvement, have occurred with ZIAGEN (abacavir). Patients who carry the HLA ‑ B*5701 allele are at a higher risk of a hypersensitivity reaction to abacavir; although, hypersensitivity reactions have occurred in patients who do not carry the HLA ‑ B*5701 allele [see Warnings and Precautions ( 5.1 )] . ZIAGEN is contraindicated in patients with a prior hypersensitivity reaction to abacavir and in HLA ‑ B*5701-positive patients [see Contraindications ( 4 ), Warnings and Precautions ( 5.1 )] . All patients should be screened for the HLA ‑ B*5701 allele prior to initiating therapy with ZIAGEN or reinitiation of therapy with ZIAGEN, unless patients have a previously documented HLA ‑ B*5701 allele assessment. Discontinue ZIAGEN immediately if a hypersensitivity reaction is...

What it is approved for

From the label in effect Sep 29, 2023.

ZIAGEN tablets and oral solution, in combination with other antiretroviral agents, are indicated for the treatment of human immunodeficiency virus (HIV-1) infection. ZIAGEN, a nucleoside analogue human immunodeficiency virus (HIV-1) reverse transcriptase inhibitor, is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. ( 1 )

Mechanism: Abacavir is an antiretroviral agent [see Microbiology ( 12.4 )] .

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • ZIAGEN · ABACAVIR SULFATE EQ 20MG BASE/ML · SOLUTION, ORAL · Prescription · TE AA

Clinical trials

Interventional ClinicalTrials.gov studies with "Abacavir" as an intervention, any sponsor and status, largest first.

All 239 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • pain748
  • pyrexia501
  • hypertension425
  • anxiety419
  • hepatic enzyme increased410
  • emotional distress409
  • headache404
  • hypersensitivity399
  • off label use396
  • anhedonia368
  • fatigue367
  • exposure during pregnancy359

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004300
2005262
2006221
2007200
2008222
2009235
2010177
2011105
2012128
2013117
2014123
2015158
2016142
2017121
2018115
2019253
2020274
2021154
2022175
2023147
2024186
2025148
202674

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

  • To Be Discontinued · updated Nov 16, 2026

    Ziagen, Injection, 20 mg/1 mL (NDC 49702-222-48). The anticipated date that ViiV will cease distribution of the product is approximately May 14, 2027.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Ziagen (Abacavir Sulfate)

2024 spending

$12K

Beneficiaries

n/a

23 claims

Per beneficiary

n/a

$1.99 per unit

View as table
YearSpending
2020$198,612
2021$180,155
2022$169,314
2023$111,586
2024$12,248

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 480 on PubMed

Sponsor: GSK

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.